Metabolic Tumor Volume Predicts for Recurrence and Death in Head-and-Neck Cancer

International Journal of Radiation Oncology Biology Physics

Volumn 74, Issue 5, 2009, Pages 1335-1341

  La, Trang H ^a   Filion, Edith J ^a   Turnbull, Brit B ^a   Chu, Jackie N ^a   Lee, Percy ^a   Nguyen, Khoa ^a   Maxim, Peter ^a   Quon, Andy ^a   Graves, Edward E ^a   Loo Jr , Billy W ^a   Le, Quynh Thu ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

Head and neck cancer; Metabolic tumor volume (MTV); Positron emission tomography (PET); Prognostic factors

Indexed keywords

18-F-FLUORODEOXYGLUCOSE; CHEMORADIOTHERAPY; COMPUTED TOMOGRAPHY; DIRECT MEASURES; DISEASE-FREE SURVIVAL; F-FLUORODEOXYGLUCOSE; FDG-PET; HEAD-AND-NECK CANCER; LOCOREGIONAL CONTROL; METABOLIC TUMOR VOLUME (MTV); OVERALL SURVIVAL; PERFORMANCE STATUS; PET SCAN; PRE-TREATMENT; PROGNOSTIC FACTORS; RISK STRATIFICATION; STANDARDIZED UPTAKE VALUES; TUMOR VOLUMES;

COMPUTERIZED TOMOGRAPHY; ELECTRONS; MEDICAL IMAGING; METABOLISM; PATIENT MONITORING; POSITRONS; RISK PERCEPTION; TUMORS;

POSITRON EMISSION TOMOGRAPHY;

CARBOPLATIN; CETUXIMAB; CISPLATIN; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; PACLITAXEL;

ADOLESCENT; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER RELAPSE; CANCER SURVIVAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEMALE; HUMAN; HYPOPHARYNX CANCER; INTENSITY MODULATED RADIATION THERAPY; LARYNX CANCER; MAJOR CLINICAL STUDY; MALE; MOUTH CANCER; NASOPHARYNX CANCER; OROPHARYNX CANCER; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; TUMOR VOLUME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; COMBINED MODALITY THERAPY; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HEAD AND NECK NEOPLASMS; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; SURVIVAL ANALYSIS; TUMOR BURDEN; YOUNG ADULT;

EID: 67651089991     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2008.10.060     Document Type: Article

References (28)

1. Wong R.J., Lin D.T., Schoder H., et al. Diagnostic and prognostic value of [(18)F] fluorodeoxyglucose positron emission tomography for recurrent head and neck squamous cell carcinoma. J Clin Oncol 20 (2002) 4199-4208
2. Tucker R., Coel M., Ko J., et al. Impact of fluorine-18 fluorodeoxyglucose on patient management: First year's experience in a clinical center. J Clin Oncol 19 (2001) 2504-2508
3. Laubenbacher C., Saumweber D., Wagner-Manslau C., et al. Comparison of fluorine-18-fluorodeoxyglucose PET, MRI and endoscopy for staging head and neck squamous cell carcinomas. J Nucl Med 36 (1995) 1747-1757
4. Schwartz D.L., Ford E., Rajendran J., et al. FDG-PET/CT imaging for preradiotherapy staging of head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 57 (2003) 129-136
5. Minn H., Maria Lapela M., and Klemi P.J. Prediction of survival with fluorine-18-fluoro-deoxyglucose and PET in head and neck cancer. J Nucl Med 38 (2007) 1907-1911
6. Allal A.S., Dulguerov P., Allaoua M., et al. Standardized uptake value of 2-[18F] fluoro-2-deoxy-D-glucose in predicting outcome in head and neck carcinomas treated by radiotherapy with or without chemotherapy. J Clin Oncol 20 (2002) 1398-1404
7. Allal A.S., Slosman D.O., Kebdani T., et al. Prediction of outcome in head-and-neck cancer patients using standardized uptake value of 2-[18F] fluoro-2-deoxy-D-glucose. Int J Radiat Oncol Biol Phys 59 (2004) 1295-1300
8. Roh J.L., Pae K.H., Choi S.H., et al. 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography as guidance for primary treatment in patients with advanced stage resectable squamous cell carcinoma of the larynx and hypopharynx. Eur J Surg Oncol 33 (2007) 790-795
9. Lee S.W., Nam S.Y., Im K.C., et al. Prediction of prognosis using standardized uptake value of 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography in nasopharyngeal carcinomas. Radiother Oncol 87 (2008) 211-216
10. Haberkorn U., Strauss L.G., Reisser C., et al. Glucose uptake, perfusion, and cell proliferation in head and neck tumors: Relation of positron emission tomography to flow cytometry. J Nucl Med 32 (1991) 1548-1555
11. Minn H., Joensuu H., Ahonen A., et al. Fluorooxyglucose imaging: A method to assess the proliferative activity of human cancer in vivo. Cancer 61 (1988) 1776-1781
12. Minn H., Clavo A.C., Grenman R., et al. In vitro comparison of cell proliferation kinetics and uptake of tritiated fluorodeoxyglucose and L-methionine in squamous cell carcinoma of the head and neck. J Nucl Med 36 (1995) 252-258
13. Perez C.A., Patel M., Chao K., et al. Carcinoma of the tonsillar fossa: Prognostic factors and long-term therapy outcome. Int J Radiat Oncol Biol Phys 42 (1998) 1077
14. Johansen L.V., Grau C., and Overgaard J. Squamous cell carcinoma of the oropharynx-An analysis of treatment results in 289 consecutive patients. Acta Oncol 39 (2000) 985
15. Graves E.E., Quon A., and Loo Jr. B.W. RT Image: An open-source tool for investigating PET in radiation oncology. Technol Cancer Res Treat 6 (2007) 111-122
16. Ciernik I.F., Dizendorf E., Baumert B.G., et al. Radiation treatment planning with an integrated positron emission and computer tomography (PET/CT): A feasibility study. Int J Radiat Oncol Biol Phys 57 (2003) 853-863
17. R Development Core Team. A language and environment for statistical computing, R Foundation for Statistical Computing, Vienna, 2006
18. Grambsch P.M., and Therneau T.M. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 81 (1994) 515-526
19. Johansen J., Buus S., Loft A., et al. Prospective study of 18FDG-PET in the detection and management of patients with lymph node metastases to the neck from an unknown primary tumor. Results from the DAHANCA-13 study. Head Neck 30 (2008) 471-478
20. Wong W.L., and Saunders M. The impact of FDG PET on the management of occult primary head and neck tumours. Clin Oncol (R Coll Radiol) 15 (2003) 461-466
21. Soto D., Piert M., and Eisbruch A. Correlation between pretreatment FDG PET biological target volume (BTV) and anatomical location of failure after radiation therapy (RT) for head and neck cancers (HNC). [Abstract]. Int J Radiat Oncol Biol Phys 69 Suppl. 1 (2007) S444-S445
22. Vernon M.R., Maheshwari M., Schultz C., et al. Clinical outcomes of patients receiving integrated PET/CT-guided radiotherapy for head and neck cancer. Int J Radiat Oncol Biol Phys 70 (2008) 678-684
23. Knegjens J.L., Pameijer F.A., Balm A.J.M., et al. Tumor volume as outcome predictor in chemoradiation for advanced head and neck cancer. [Abstract]. Int J Radiat Oncol Biol Phys 69 Suppl. 1 (2007) S410-S411
24. Lee P., Weerasuriya D.K., Lavori P.W., et al. Metabolic tumor volume predicts for disease progression and death in lung cancer. Int J Radiat Oncol Biol Phys 69 (2007) 328-333
25. Grow A., Quon A., Graves E.E., et al. Metabolic tumor volume as an independent prognostic factor in lymphoma. J Clin Oncol (ASCO Annual Meeting Proceedings Supplement) 23 (2005) 6594
26. Adelstein D.J., Saxton J.P., Rybicki L.A., et al. Multiagent concurrent chemoradiotherapy for locoregionally advanced squamous cell head and neck cancer: Mature results from a single institution. J Clin Oncol 24 (2006) 1064-1071
27. Adelstein D.J., Li Y., Adams G.L., et al. An Intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 21 (2003) 92-98
28. Bonner J.A., Harari P.M., Jiralt J., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354 (2006) 567-578